Copyright Reports & Markets. All rights reserved.

Global Chimeric Antigen Receptor Cell Therapy Market 2019 by Company, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Chimeric Antigen Receptor Cell Therapy Market Overview

    • 1.1 Product Overview and Scope of Chimeric Antigen Receptor Cell Therapy
    • 1.2 Classification of Chimeric Antigen Receptor Cell Therapy by Types
      • 1.2.1 Global Chimeric Antigen Receptor Cell Therapy Revenue Comparison by Types (2019-2024)
      • 1.2.2 Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Types in 2018
      • 1.2.3 Monotherapy
      • 1.2.4 Combination Therapy
    • 1.3 Global Chimeric Antigen Receptor Cell Therapy Market by Application
      • 1.3.1 Global Chimeric Antigen Receptor Cell Therapy Market Size and Market Share Comparison by Applications (2014-2024)
      • 1.3.2 Acute Leukemia
      • 1.3.3 Non-hodgkin's Lymphoma
      • 1.3.4 Multiple Myeloma
      • 1.3.5 Transplant Rejection
      • 1.3.6 Other
    • 1.4 Global Chimeric Antigen Receptor Cell Therapy Market by Regions
      • 1.4.1 Global Chimeric Antigen Receptor Cell Therapy Market Size (Million USD) Comparison by Regions (2014-2024)
      • 1.4.1 North America (USA, Canada and Mexico) Chimeric Antigen Receptor Cell Therapy Status and Prospect (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Chimeric Antigen Receptor Cell Therapy Status and Prospect (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Chimeric Antigen Receptor Cell Therapy Status and Prospect (2014-2024)
      • 1.4.4 South America (Brazil, Argentina, Colombia) Chimeric Antigen Receptor Cell Therapy Status and Prospect (2014-2024)
      • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Chimeric Antigen Receptor Cell Therapy Status and Prospect (2014-2024)
    • 1.5 Global Market Size of Chimeric Antigen Receptor Cell Therapy (2014-2024)

    2 Manufacturers Profiles

    • 2.1 Amgen Inc
      • 2.1.1 Business Overview
      • 2.1.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Amgen Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Autolus Therapeutics Plc
      • 2.2.1 Business Overview
      • 2.2.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Autolus Therapeutics Plc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 Beijing Immunochina Medical Science & Technology Co Ltd
      • 2.3.1 Business Overview
      • 2.3.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 Beijing Immunochina Medical Science & Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Bellicum Pharmaceuticals Inc
      • 2.4.1 Business Overview
      • 2.4.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Bellicum Pharmaceuticals Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Bristol-Myers Squibb Co
      • 2.5.1 Business Overview
      • 2.5.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Bristol-Myers Squibb Co Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 bluebird bio Inc
      • 2.6.1 Business Overview
      • 2.6.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 bluebird bio Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 CARsgen Therapeutics Ltd
      • 2.7.1 Business Overview
      • 2.7.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 CARsgen Therapeutics Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 Celgene Corp
      • 2.8.1 Business Overview
      • 2.8.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 Celgene Corp Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Cell Medica Ltd
      • 2.9.1 Business Overview
      • 2.9.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Cell Medica Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.10 Cellular Biomedicine Group Inc
      • 2.10.1 Business Overview
      • 2.10.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.10.2.1 Product A
        • 2.10.2.2 Product B
      • 2.10.3 Cellular Biomedicine Group Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.11 Celularity Inc
      • 2.11.1 Business Overview
      • 2.11.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.11.2.1 Product A
        • 2.11.2.2 Product B
      • 2.11.3 Celularity Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.12 Celyad SA
      • 2.12.1 Business Overview
      • 2.12.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.12.2.1 Product A
        • 2.12.2.2 Product B
      • 2.12.3 Celyad SA Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.13 Daiichi Sankyo Co Ltd
      • 2.13.1 Business Overview
      • 2.13.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.13.2.1 Product A
        • 2.13.2.2 Product B
      • 2.13.3 Daiichi Sankyo Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.14 Fosun Pharmaceutical AG
      • 2.14.1 Business Overview
      • 2.14.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.14.2.1 Product A
        • 2.14.2.2 Product B
      • 2.14.3 Fosun Pharmaceutical AG Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.15 Gilead Sciences Inc
      • 2.15.1 Business Overview
      • 2.15.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.15.2.1 Product A
        • 2.15.2.2 Product B
      • 2.15.3 Gilead Sciences Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.16 Guangzhou Anjie Biomedical Technology Co Ltd
      • 2.16.1 Business Overview
      • 2.16.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.16.2.1 Product A
        • 2.16.2.2 Product B
      • 2.16.3 Guangzhou Anjie Biomedical Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.17 Hangzhou Converd Co Ltd
      • 2.17.1 Business Overview
      • 2.17.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.17.2.1 Product A
        • 2.17.2.2 Product B
      • 2.17.3 Hangzhou Converd Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.18 Hebei Senlang Biotechnology Inc Ltd
      • 2.18.1 Business Overview
      • 2.18.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.18.2.1 Product A
        • 2.18.2.2 Product B
      • 2.18.3 Hebei Senlang Biotechnology Inc Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.19 HRAIN Biotechnology Co Ltd
      • 2.19.1 Business Overview
      • 2.19.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.19.2.1 Product A
        • 2.19.2.2 Product B
      • 2.19.3 HRAIN Biotechnology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.20 Juno Therapeutics Inc
      • 2.20.1 Business Overview
      • 2.20.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.20.2.1 Product A
        • 2.20.2.2 Product B
      • 2.20.3 Juno Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.21 Kite Pharma Inc
      • 2.21.1 Business Overview
      • 2.2.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.21.2.1 Product A
        • 2.21.2.2 Product B
      • 2.21.3 Kite Pharma Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.22 Nanjing Legend Biotech Co Ltd
      • 2.22.1 Business Overview
      • 2.22.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.22.2.1 Product A
        • 2.22.2.2 Product B
      • 2.22.3 Nanjing Legend Biotech Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.23 NantKwest Inc
      • 2.23.1 Business Overview
      • 2.23.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.23.2.1 Product A
        • 2.23.2.2 Product B
      • 2.23.3 NantKwest Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.24 Nkarta Inc
      • 2.24.1 Business Overview
      • 2.24.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.24.2.1 Product A
        • 2.24.2.2 Product B
      • 2.24.3 Nkarta Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.25 Novartis AG
      • 2.25.1 Business Overview
      • 2.25.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.25.2.1 Product A
        • 2.25.2.2 Product B
      • 2.25.3 Novartis AG Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.26 Ono Pharmaceutical Co Ltd
      • 2.26.1 Business Overview
      • 2.26.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.26.2.1 Product A
        • 2.26.2.2 Product B
      • 2.26.3 Ono Pharmaceutical Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.27 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
      • 2.27.1 Business Overview
      • 2.27.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.27.2.1 Product A
        • 2.27.2.2 Product B
      • 2.27.3 Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.28 Sorrento Therapeutics Inc
      • 2.28.1 Business Overview
      • 2.28.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.28.2.1 Product A
        • 2.28.2.2 Product B
      • 2.28.3 Sorrento Therapeutics Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)
    • 2.29 Takara Bio Inc
      • 2.29.1 Business Overview
      • 2.29.2 Chimeric Antigen Receptor Cell Therapy Type and Applications
        • 2.29.2.1 Product A
        • 2.29.2.2 Product B
      • 2.29.3 Takara Bio Inc Chimeric Antigen Receptor Cell Therapy Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Chimeric Antigen Receptor Cell Therapy Market Competition, by Players

    • 3.1 Global Chimeric Antigen Receptor Cell Therapy Revenue and Share by Players (2014-2019)
    • 3.2 Market Concentration Rate
      • 3.2.1 Top 5 Chimeric Antigen Receptor Cell Therapy Players Market Share
      • 3.2.2 Top 10 Chimeric Antigen Receptor Cell Therapy Players Market Share
    • 3.3 Market Competition Trend

    4 Global Chimeric Antigen Receptor Cell Therapy Market Size by Regions

    • 4.1 Global Chimeric Antigen Receptor Cell Therapy Revenue and Market Share by Regions
    • 4.2 North America Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 4.3 Europe Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 4.5 South America Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

    5 North America Chimeric Antigen Receptor Cell Therapy Revenue by Countries

    • 5.1 North America Chimeric Antigen Receptor Cell Therapy Revenue by Countries (2014-2019)
    • 5.2 USA Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 5.3 Canada Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 5.4 Mexico Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

    6 Europe Chimeric Antigen Receptor Cell Therapy Revenue by Countries

    • 6.1 Europe Chimeric Antigen Receptor Cell Therapy Revenue by Countries (2014-2019)
    • 6.2 Germany Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 6.3 UK Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 6.4 France Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 6.5 Russia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 6.6 Italy Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

    7 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Countries

    • 7.1 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue by Countries (2014-2019)
    • 7.2 China Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 7.3 Japan Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 7.4 Korea Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 7.5 India Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

    8 South America Chimeric Antigen Receptor Cell Therapy Revenue by Countries

    • 8.1 South America Chimeric Antigen Receptor Cell Therapy Revenue by Countries (2014-2019)
    • 8.2 Brazil Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 8.3 Argentina Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 8.4 Colombia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

    9 Middle East and Africa Revenue Chimeric Antigen Receptor Cell Therapy by Countries

    • 9.1 Middle East and Africa Chimeric Antigen Receptor Cell Therapy Revenue by Countries (2014-2019)
    • 9.2 Saudi Arabia Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 9.3 UAE Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 9.4 Egypt Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 9.5 Nigeria Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)
    • 9.6 South Africa Chimeric Antigen Receptor Cell Therapy Revenue and Growth Rate (2014-2019)

    10 Global Chimeric Antigen Receptor Cell Therapy Market Segment by Type

    • 10.1 Global Chimeric Antigen Receptor Cell Therapy Revenue and Market Share by Type (2014-2019)
    • 10.2 Global Chimeric Antigen Receptor Cell Therapy Market Forecast by Type (2019-2024)
    • 10.3 Monotherapy Revenue Growth Rate (2014-2024)
    • 10.4 Combination Therapy Revenue Growth Rate (2014-2024)

    11 Global Chimeric Antigen Receptor Cell Therapy Market Segment by Application

    • 11.1 Global Chimeric Antigen Receptor Cell Therapy Revenue Market Share by Application (2014-2019)
    • 11.2 Chimeric Antigen Receptor Cell Therapy Market Forecast by Application (2019-2024)
    • 11.3 Acute Leukemia Revenue Growth (2014-2019)
    • 11.4 Non-hodgkin's Lymphoma Revenue Growth (2014-2019)
    • 11.5 Multiple Myeloma Revenue Growth (2014-2019)
    • 11.6 Transplant Rejection Revenue Growth (2014-2019)
    • 11.7 Other Revenue Growth (2014-2019)

    12 Global Chimeric Antigen Receptor Cell Therapy Market Size Forecast (2019-2024)

    • 12.1 Global Chimeric Antigen Receptor Cell Therapy Market Size Forecast (2019-2024)
    • 12.2 Global Chimeric Antigen Receptor Cell Therapy Market Forecast by Regions (2019-2024)
    • 12.3 North America Chimeric Antigen Receptor Cell Therapy Revenue Market Forecast (2019-2024)
    • 12.4 Europe Chimeric Antigen Receptor Cell Therapy Revenue Market Forecast (2019-2024)
    • 12.5 Asia-Pacific Chimeric Antigen Receptor Cell Therapy Revenue Market Forecast (2019-2024)
    • 12.6 South America Chimeric Antigen Receptor Cell Therapy Revenue Market Forecast (2019-2024)
    • 12.7 Middle East and Africa Chimeric Antigen Receptor Cell Therapy Revenue Market Forecast (2019-2024)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Scope of the Report:
      The global Chimeric Antigen Receptor Cell Therapy market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024.
      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Chimeric Antigen Receptor Cell Therapy.
      Europe also play important roles in global market, with market size of xx million USD in 2019 and will be xx million USD in 2024, with a CAGR of xx%.
      This report studies the Chimeric Antigen Receptor Cell Therapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Chimeric Antigen Receptor Cell Therapy market by product type and applications/end industries.

      Market Segment by Companies, this report covers
      Amgen Inc
      Autolus Therapeutics Plc
      Beijing Immunochina Medical Science & Technology Co Ltd
      Bellicum Pharmaceuticals Inc
      Bristol-Myers Squibb Co
      bluebird bio Inc
      CARsgen Therapeutics Ltd
      Celgene Corp
      Cell Medica Ltd
      Cellular Biomedicine Group Inc
      Celularity Inc
      Celyad SA
      Daiichi Sankyo Co Ltd
      Fosun Pharmaceutical AG
      Gilead Sciences Inc
      Guangzhou Anjie Biomedical Technology Co Ltd
      Hangzhou Converd Co Ltd
      Hebei Senlang Biotechnology Inc Ltd
      HRAIN Biotechnology Co Ltd
      Juno Therapeutics Inc
      Kite Pharma Inc
      Nanjing Legend Biotech Co Ltd
      NantKwest Inc
      Nkarta Inc
      Novartis AG
      Ono Pharmaceutical Co Ltd
      Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
      Sorrento Therapeutics Inc
      Takara Bio Inc

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Monotherapy
      Combination Therapy

      Market Segment by Applications, can be divided into
      Acute Leukemia
      Non-hodgkin's Lymphoma
      Multiple Myeloma
      Transplant Rejection
      Other

      Buy now